DsiRNA Citations

  1. Knockdown of β-catenin with Dicer-substrate siRNAs reduces liver tumor burden in vivo
    Dudek H, Wong DH, Arvan R, Shah A, Wortham K, Ying B, Diwanji R, Zhou W, Holmes B, Yang H, Cyr WA, Zhou Y, Shah A, Farkiwala R, Lee M, Li Y, Rettig GR, Collingwood MA, Basu SK, Behlke MA, Brown BD
    Mol Ther, 22(1):92–101 (2014)
  2. Inosine-mediated modulation of RNA sensing by Toll-like receptor 7 (TLR7) and TLR8
    Sarvestani ST, Tate MD, Moffat, JM, Jacobi AM, Behlke, MA, Miller AR, Beckham SA, McCoy CE, Chen W, Mintern JD, O’Keeffe M, John M, Williams BR, Gantier MP
    J Virol, 88(2):799–810 (2014)
  3. In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV-driven tumours
    Khairuddin N, Blake SJ, Firdaus F, Steptoe RJ, Behlke MA, Hertzog PJ, McMillan NA
    Immunol Cell Biol, 92(2):156–163 (2014)
  4. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge
    Zhou J, Neff CP, et al
    Mol Ther, 21(1):192–200 (2013)
    Efficient, noncovalent binding of Dicer-substrate siRNAs (DsiRNAs) to an aptamer for effective in vivo knockdown of target mRNAs and potent inhibition of HIV-1 replication.
  5. Synthetic Dicer-Substrate siRNAs as Triggers of RNA Interference
    Rose S, Behlke MD
    In: Howard KA (editor) RNA Interference from Biology to Therapeutics: Advances in Delivery Science and Technology: Springer US, :31–56 (2013)
  6. Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants
    Snead NM, Wu X, et al
    Nucleic Acids Res, 41(12):6209–6221 (2013)
  7. Knockdown of Ki-67 by Dicer-substrate small interfering RNA sensitizes bladder cancer cells to curcumin-induced tumor inhibition
    Pichu S, Krishnamoorthy S, et al
    PLoS One, 7(11):e48567 (2012)
    Bladder cancer cells pretreated with Dicer-substrate siRNA (DsiRNA) against Ki-67, a DNA-binding protein associated with cell proliferation proliferation, promotes cell cycle arrest and enhances curcumin-induced apoptosis.
  8. RNA interference in vitro and in vivo using DsiRNA targeting the nucleocapsid N mRNA of human metapneumovirus
    Darniot M, Schildgen V, et al
    Antiviral Res, 93(3):364–373 (2012)

    Use of DsiRNAs to inhibit viral replication of metapneumovirus in vitro and in vivo. The authors report highly specific inhibition achieved without induction of cytokines or off-target effects.

  9. A miR-19 regulon that controls NF-kB signaling
    Gantier MP, Stunden HJ, McCoy CE, Behlke MA, et al
    Nucleic Acids Res, 40(16):8048–8058 (2012)
    miRNA antagonists (AMOs) to selected miR-19 family members  and Dicer-substrate siRNAs (DsiRNAs) targeting RNF11 and EGFP (target and control, respectively) are used in a study to show that targeting miR-19 and linked family members may regulate NF-kappaB signalling in inflammation.
  10. Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: In vivo targeting of Kupffer cells by siRNA-liposomes
    Pichu S, Krishnamoorthy S, et al
    Pharmacol Res, 65(1):48–55 (2012)

    Use of DsiRNAs to inhibit TNF-ɑ secretion in the study of inflammatory diseases. Data shows greater effectiveness of 27mer DsiRNAs than 21mers.

  11. T-cell activation is enhanced by targeting IL-10 cytokine production in toll-like receptor- stimulated macrophages
    Walk RM, Elliot ST, Blanco FC, Snyder JA, Jacobi AM, Rose SD, Behlke MA, Salem AK, Vukmanovic S, Sandler AD
    ImmunoTargets and Therapy, 1:13–23 (2012)
    Use of Dicer-substrate siRNAs (DsiRNAs) for effective in vitro and in vivo suppression of IL-10 cytokine in primary bone marrow macrophages and A/J mice, respectively.
  12. MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model
    te Boekhorst BCM, Jensen LB, et al
    J Control Release, 161(3):772–780 (2012)
  13. An aptamer-siRNA chimera supressed HIV-1 viral loads and protects from helper CD4+ T cell decline in humanized mice
    Neff CP, Zhou J, et al
    Sci Transl Med, 3(66):66ra6 (2011)

    Use of an RNA aptamer–siRNA chimera that triggers sequence-specific degradation of HIV RNAs to suppress HIV-1 replication and prevent CD4+ T cell depletion in humanized mice.

  14. Aptamer-targeted cell-specific RNA interference
    Zhou J and Rossi JJ
    Silence, 1(1):4–13 (2010)

    A review summarizing the use of cell-internalizing aptamers to deliver siRNAs to target cells. Highlights the optimization and improvement of aptamer-targeted siRNAs for clinical translation.

  15. Direct application of siRNA for in vivo pain research
    Sarret P, Doré-Savard L, Beaudet N
    Methods in Molecular Biology, 623:383–395 (2010)
    Dicer-substrate RNA (DsiRNA) is used to target physiological pain modulators in animal models for in vivo pain research.
  16. Competition between siRNA duplexes: impact of RNA-induced silencing complex loading efficiency and comparison between conventional-21 bp and Dicer-substrate siRNAs
    Tanudji M, Machalek D, et al
    Oligonucleotides, 20(1):27–32 (2010)
  17. Chitosan/siRNA nanoparticle-mediated TNF-α knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model
    Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J
    Mol Ther, 17(1):162–168 (2009)
    DsiRNAs targeting TNF-α, administered intraperitoneally using chitosan nanoparticles, reduce inflammation in murine collagen-induced arthritis.
  18. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells
    Zhoud J, Swiderski P, et al
    Nucleic Acids Res, 37(9):3094–3109 (2009)

    Use of aptamers and aptamer–siRNA chimeras to inhibit HIV-1 replication and infectivity in cultured human CEM T cells and primary blood mononuclear cells.

  19. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
    Kortylewski M, Swiderski P, et al
    Nat Biotechnol, 27(10):925–932 (2009)
    Use of a novel CpG-motif oligonucleotide delivery tool to deliver anti-STAT3 DsiRNA to TLR9-positive cells, where Dicer cleavage releases the mature siRNA from the CpG ligand
  20. Functional polarity is introduced by Dicer processing of short substrate RNAs
    Rose SD, Kim D-H, Amarzguioui M, Heidel JD, Collingwood MA, Davis ME, Rossi JJ, Behlke MA
    J Biomol Tech, 33(13):4140–4156 (2005)
  21. Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy
    Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ
    Nat Biotechnol, 23(2):222–226 (2005)